Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Podar

Showing results (41-50 of 150) with videos related to

Pageof 15
Sort By:
Blood|February 7, 2002
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cellsYu-Tzu Tai, Klaus Podar, Deepak Gupta, et al.
EMBO Molecular Medicine|March 25, 2025
PARP7 as a new target for activating anti-tumor immunity in cancerKaterina Popova, Johannes Benedum, Magdalena Engl, et al.
Annals of Hematology|January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myelomaIris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Plos One|March 3, 2016
Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET PathwaySonia Vallet, Muhammad Hasan Bashari, Feng-Juan Fan, et al.
Oncogene|September 19, 2003
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cellsDharminder Chauhan, Guilan Li, Martin Sattler, et al.
Cancer Letters|January 26, 2025
Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemiaStefanie Weiss, Bernhard Zdársky, Agnieszka Witalisz-Siepracka, et al.
The Journal of Biological Chemistry|April 1, 2003
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Molecular Cancer Therapeutics|December 14, 2002
The biological sequelae of stromal cell-derived factor-1alpha in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.
Blood|November 17, 2007
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaDharminder Chauhan, Ajita Singh, Mohan Brahmandam, et al.
Oncogene|April 20, 2004
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341Dharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Pageof 15

Showing results (41-50 of 150) with videos related to

Sort By:
Pageof 15
Blood|February 7, 2002
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cellsYu-Tzu Tai, Klaus Podar, Deepak Gupta, et al.
EMBO Molecular Medicine|March 25, 2025
PARP7 as a new target for activating anti-tumor immunity in cancerKaterina Popova, Johannes Benedum, Magdalena Engl, et al.
Annals of Hematology|January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myelomaIris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Plos One|March 3, 2016
Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET PathwaySonia Vallet, Muhammad Hasan Bashari, Feng-Juan Fan, et al.
Oncogene|September 19, 2003
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cellsDharminder Chauhan, Guilan Li, Martin Sattler, et al.
Cancer Letters|January 26, 2025
Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemiaStefanie Weiss, Bernhard Zdársky, Agnieszka Witalisz-Siepracka, et al.
The Journal of Biological Chemistry|April 1, 2003
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Molecular Cancer Therapeutics|December 14, 2002
The biological sequelae of stromal cell-derived factor-1alpha in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.
Blood|November 17, 2007
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaDharminder Chauhan, Ajita Singh, Mohan Brahmandam, et al.
Oncogene|April 20, 2004
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341Dharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Pageof 15